Abstract：Objective:To explore the influence of pirarubicin intravesical therapy on serum soluble intercellular adhesion molecule-1 (sICAM-1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in patients with superficial bladder cancer (SBC). Methods:132 patients with SBC undergoing transurethral resection of bladder tumor (TURBT) were divided into control group and observation group according to the treatments, with 66 cases in each group. The patients in control group received mitomycin intravesical therapy after TURBT and those in observation group received pirarubicin intravesical therapy. The recurrence rate within 2 years after surgery and complication during treatment were observed in two groups. The changes in serum sICAM-1, VEGF and MMP-9 were compared between two groups 6 months after surgery. Results:The recurrence rate within 2 years after surgery in observation group was significantly lower than in control group, while the recurrence rate during 6 to 12 months after surgery and ectopic recurrence rate in observation group were significantly lower than in control group (P<0.05). The time of recurrence in observation group was significantly later than in control group (P<0.05). The serum sICAM-1, VEGF and MMP-9 levels were significantly reduced in two groups 6 months after surgery as compared with those before operation and those indexes in observation group were lower than in control group (P<0.05). There was no significant difference in complications between two groups during intravesical therapy (P>0.05). Conclusions:Intravesicaltherapy of pirarubicin can effectively reduce
[1] 薛斌,何秉勋,康厚彬,等.经尿道膀胱肿瘤电切术联合吡柔比星膀胱灌注治疗对浅表性膀胱癌患者预后及血清相关因子的影响.实用癌症杂志,2016,31(6):1027-1029.
[2] Solanki AA, Martin B, Korpics M, et al.Bladder-preserving therapy patterns of care: a survey of US radiation oncologists. Int J Radiat Oncol Biol Phys, 2017,99(2):383-387.
[3] 裴利旗. 经尿道膀胱肿瘤电切术联合吡柔比星膀胱灌注治疗浅表性膀胱癌.现代中西医结合杂志,2016,25(30):3365-3367.
[4] 胡映秋,王晓荣,谢梅茂,等.吡柔比星与吉西他滨膀胱灌注化疗治疗膀胱癌的疗效比较.现代肿瘤医学,2015,23(17):2463-2466.
[5] 王琦,徐佳伟,欧彤文,等.经尿道膀胱肿瘤切除术后联合髂内动脉化疗治疗肌层浸润性膀胱癌疗效分析.微创泌尿外科杂志,2016,5(4):229-232.
[6] Gontero P, Sylvester R, Pisano F, et al.Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol, 2015,67(1):74-82.
[7] 邱志磊,牛海涛,孙光.2005年欧洲泌尿外科会议膀胱癌诊断治疗纲要.临床泌尿外科杂志,2006,21(4):318-320.
[8] 曹倪豪,周飞,张锦华,等.吡柔比星术后即刻膀胱灌注联合复方苦参注射液治疗浅表性膀胱癌的机制研究.海南医学院学报,2017,23(2):189-192.
[9] 白大应,刘杰,王云杰,等.二次电切联合吡柔比星即刻灌注治疗非肌层浸润性膀胱癌临床疗效观察.微创泌尿外科杂志,2018,7(1):61-64.
[10] 李金乾,武跃清,秦克松,等.浅表性膀胱癌经尿道膀胱肿瘤电切术联合丝裂霉素C及干扰素治疗效果与复发原因.中国临床医生杂志,2018,46(1):65-67.
[11] Porten SP, Leapman MS, Greene KL.Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol, 2015,31(4):297-303.
[12] Meng E, Hsu YC, Chuang YC.Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Low Urin Tract Symptoms, 2018,10(1):3-11.
[13] Sallami S, Khouni H, Ben Atta M, et al.Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases. Tunis Med, 2016,94(12):844.
[14] 张选举,江铎,熊丙建,等.丝裂霉素与吡柔比星膀胱灌注化疗对膀胱癌术后患者VEGF,FGF及MMP-9水平的影响.实用癌症杂志,2017,32(9):1550-1552.
[15] He X, Li J, Guo W, et al.Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget, 2015,6(4):2302-2314.
[16] 王群,胡卫红,胡乃刚.多柔比星灌注治疗对行TURBT术后浅表性膀胱癌患者临床疗效及相关指标的影响.中国药房,2017,28(36):5091-5094.
[17] 张林超,孙继建,潘世杰,等.复方苦参注射液对膀胱癌细胞增殖,侵袭的影响及相关机制分析.中药材,2017,40(5):1208-1211.
[18] Ricci S, Bruzzese D, Di Carlo A.Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. Oncol Lett, 2015,10(4):2527-2532.
[19] 钟鹏,杨川.血清P53,MMP-7,MMP-9在膀胱癌患者中的表达及意义.国际检验医学杂志,2018,39(9):1052-1055.
